Catalog No.
Product Name
Application
Product Information
Citations
- PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects.
-
CD206 Targeting Peptide
RP-182 is a synthetic immunomodulatory peptide that targets the mannose receptor CD206 on tumor-associated macrophages (TAMs), exhibiting a dissociation constant (Kd) of 8 μM. By inducing a conformational change in the CD206 receptor, RP-182 activates NF-κB signaling, promoting TNFα secretion and phagocytosis in CD206high TAMs, ultimately leading to apoptosis via caspase 8 activation. This compound is valuable for research in pancreatic cancer and melanoma, providing insights into therapeutic strategies that enhance anti-tumor immunity. -
CD38 inhibitor
MK-0159 is an orally active, potent, and selective inhibitor of CD38, with IC₅₀ values of 22 nM for human, 3 nM for mouse, and 70 nM for rat CD38. It exhibits good microsomal stability in both human and rodent liver microsomes. MK-0159 effectively increases NAD⁺ (nicotinamide adenine dinucleotide) levels and decreases ADPR (adenosine diphosphate ribose) concentrations in whole blood and heart tissue, making it a promising compound for research in metabolic, cardiovascular, and age-related diseases. -
CD11b agonist.
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active, allosteric agonist of CD11b, an integrin subunit expressed on myeloid cells. By activating CD11b, ADH-503 promotes the repolarization of tumor-associated macrophages (TAMs) toward a pro-inflammatory phenotype, reduces the infiltration of immunosuppressive myeloid cells into tumors, and enhances dendritic cell responses. These immunomodulatory effects support its potential use in cancer immunotherapy. -
CD38 inhibitor
RBN013209 is an orally active, small molecule inhibitor of CD38, exhibiting potent inhibitory activity with an IC₅₀ ranging from 0.01 to 0.1 μM against human CD38. It effectively blocks the enzymatic conversion of extracellular NAD⁺ to ADPR and cADPR in both tumor cells and peripheral blood mononuclear cells (PBMCs), thereby modulating the tumor microenvironment. Beyond its direct antitumor potential, RBN013209 also enhances the efficacy of immunotherapies. It preserves the naïve and central memory phenotypes of CAR-T cells, while reducing the expression of activation markers and exhaustion-associated inhibitory receptors. These properties position RBN013209 as a promising agent for both tumor research and the development of combination strategies to improve CAR-T cell persistence and function. -
Anti-TNFRSF17/CD3E Antibody
Gamgertamig is a humanized IgG4 bispecific antibody that simultaneously targets TNFRSF17 and CD3E. This antibody exhibits potent immunomodulatory activity by activating T cells in the presence of TNFRSF17-expressing cells, making it a valuable tool for enhancing anti-tumor immune responses. It is ideal for research applications in cancer immunotherapy and provides insights into T cell modulation and tumor microenvironment interactions. -
CD28 Inhibitor
CD28-IN-3 is a selective CD28 inhibitor that effectively interrupts the CD28-B7 interaction, with an IC50 of 7.80 μM and a Kd of 52.45 μM. This compound significantly suppresses the production of key proinflammatory cytokines, including IFN-γ, IL-2, and TNF-α. CD28-IN-3 is valuable for research focused on checkpoint-resistant cancers, providing insights into immune modulation and potential therapeutic strategies. -
CD28 Inhibitor
CD28-IN-1 is a selective inhibitor of CD28 with a dissociation constant (KD) of 12.48 μM. It effectively disrupts the CD28-B7 interactions, leading to a significant reduction in CD28-mediated immune activation. This compound has been shown to suppress cytokine production, including IFN-γ, IL-2, and TNF-α, in primary human T cells when co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 is suitable for research focused on tumor immunity and T cell modulation. -
Anti-CD274/TNFRSF9 Antibody
Solabafusp alfa is a humanized IgG4κ type antibody that specifically targets CD274 (also known as PD-L1) and TNFRSF9 (also known as 4-1BB). This compound is significant for its potential to modulate immune responses, making it a valuable tool in cancer research and immunotherapy studies. It can be utilized to explore pathways related to immune checkpoint inhibition and T-cell activation. An appropriate isotype control for this antibody is Human IgG4 (S228P) kappa. -
CD206 Targeting Peptide
RP-832c is a synthetic analogue of host defense peptides that selectively targets the mannose receptor CD206 on M2 polarized macrophages (Kd = 3.5 μM). Binding of RP-832c to CD206 induces significant conformational changes, activating signaling pathways that promote apoptosis and repolarization of M2 macrophages to an M1 phenotype. The treatment with RP-832c effectively reduces CD206 gene expression while transiently increasing TNF-α levels, a hallmark of M1 macrophages. This reagent is valuable for research on T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF). -
CD27 Agonist
MG-C-30 is a potent oral agonist of CD27, demonstrating an EC50 of 0.84 μM. This compound activates natural killer (NK) cells and enhances T cell co-stimulatory signals, thereby augmenting the immune response. MG-C-30 has also shown significant antitumor efficacy in the EG7-OVA mouse model, making it a valuable tool for research in immunotherapy and cancer treatment. -
GPRC5D/CD3ε/TNFRSF17 Antibody
Ramantamig is a humanized monoclonal antibody that targets CD3ε on T cells, as well as GPRC5D and TNFRSF17 (BCMA) on multiple myeloma cells. It facilitates T-cell-mediated cytotoxicity by forming immunological synapses, leading to selective killing of myeloma cells without non-specific T-cell activation when target cells are absent. Additionally, Ramantamig has been engineered to minimize interactions with Fc receptors, enhancing its specificity. This reagent is ideal for research in multiple myeloma therapies. -
CD47-SIRPα axis Inhibitor
DMUP is a potent inhibitor of the CD47-SIRPα axis. This compound promotes apoptosis and enhances macrophage phagocytosis in A549 lung cancer cells, while also reducing the expression of CD47 and SIRPα proteins. DMUP demonstrates significant antitumor activity, making it a valuable tool for research in cancer immunotherapy and macrophage biology. -
Anti-EGFR/CD47 Antibody
Vislarafusp alfa is a humanized IgG1κ antibody targeting both EGFR and CD47. This novel bispecific antibody exhibits potential for modulating tumor immune evasion and promoting anti-tumor responses, making it significant in cancer research applications. Its unique mechanism of action presents valuable opportunities for studying combination therapies and understanding the interplay between immune checkpoint regulators and growth factor signaling pathways. -
NCD38 Enantiomer
(1R,2S)-NCD38 TFA is a selective inhibitor of Lysine-specific demethylase 1 (LSD1). This enantiomeric form of NCD38 TFA exhibits potent biological activity, primarily in the modulation of epigenetic regulation through LSD1 inhibition. It is applicable in research focused on cancer biology, developmental studies, and potential therapeutic interventions targeting LSD1-related pathways. -
TNFSF13B/BAFF/CD257 Inhibitor
Aritinercept is a recombinant fusion protein that functions as an inhibitor of TNFSF13B (BAFF/CD257). This compound effectively neutralizes BAFF and APRIL, leading to reduced B cell proliferation and suppression of peripheral B cells, along with a decrease in serum immunoglobulins. Aritinercept has demonstrated beneficial effects in a mouse model of systemic lupus erythematosus (SLE) by lowering markers of renal damage, as well as reducing levels of IFNγ, IL-17A, and anti-dsDNA autoantibodies. This reagent is suitable for research focused on systemic lupus erythematosus and related autoimmune disorders. -
CD206 Targeted Fluorescent Dye
MR2-cy5 is a fluorescent dye specifically designed to target CD206, a receptor expressed on macrophages. This reagent enables precise tracking of CD206+ macrophages in various biological samples, facilitating studies in immunology and cellular biology. MR2-cy5 is ideal for applications such as flow cytometry and imaging, contributing to the understanding of macrophage function and behavior in health and disease. -
anti-CD22-Calecheamicin Conjugate
Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, composed of a humanized anti-CD22 antibody linked to the cytotoxic agent Calicheamicin. This compound exhibits potent efficacy against CD22-positive B-cell non-Hodgkin’s lymphoma and is being investigated for its potential in treating acute lymphoblastic leukemia. Researchers can utilize Inotuzumab ozogamicin to explore therapeutic strategies for CD22-expressing malignancies. -
Anti-CLDN18/CD3E Antibody
Emaretamig is a humanized IgG1κ monoclonal antibody that selectively targets CLDN18 and CD3E. This compound exhibits significant anti-tumor efficacy and is primarily employed in research on gastric and pancreatic cancers. Its mechanism of action facilitates T-cell engagement with tumor cells, enhancing immune-mediated responses against malignancies expressing these antigens. -
Anti CLDN18.2 & CD3E Antibody
Lumivatamig is a bispecific antibody designed to target CLDN18.2 and CD3E, facilitating T-cell-mediated cytotoxicity against CLDN18.2-expressing tumors. This dimer-type H-γ1_L-κ-scFvhl antibody is employed in cancer immunotherapy research to enhance anti-tumor immune responses. Its ability to bridge tumor cells and T cells may contribute to improved therapeutic outcomes in clinical applications targeting gastric and pancreatic cancers. -
CD33 ADC Antibody
Gemtuzumab is a monoclonal IgG4-κ antibody that targets the CD33 antigen. This antibody mediates cell necrosis by specifically binding to CD33 expressed on leukemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab serves as a precursor for the synthesis of antibody-drug conjugates, such as Gemtuzumab ozogamicin, which combines a cytotoxic derivative of Calicheamicin with the antibody. It is utilized in research applications focused on understanding and treating acute myeloid leukemia. -
Anti-Albumin/FOLR1/CD3 Antibody
Eliroptamig is a multispecific antibody that targets albumin, folate receptor α (FOLR1), and cluster of differentiation 3 (CD3). This antibody enhances its half-life through binding to albumin, while effectively targeting FOLR1 on tumor cells and engaging T cells to facilitate targeted tumor destruction. It is valuable in cancer research applications, particularly in studies focusing on immunotherapy and tumor microenvironment interactions. -
ENTPD1/CD39 Antibody
Mebarase alfa is a human monoclonal antibody directed against ENTPD1/CD39. This reagent is particularly useful for investigating sepsis-associated renal injury, facilitating research into mechanisms of renal dysfunction and potential therapeutic interventions. Its specificity for ENTPD1/CD39 enables detailed exploration of immune regulation and purinergic signaling in pathophysiological contexts. -
CD36 Ligand
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine that targets scavenger receptor class B, specifically CD36. This compound accumulates at sites of oxidative stress in vivo and is implicated in the molecular mechanisms of tumor apoptosis. Its interaction with oxidized phospholipids (oxPLs) suggests potential applications in cancer research and studies related to oxidative stress and inflammation. -
CD36 Inhibitor
1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC is a unique oxidized phospholipid that functions as a potent CD36 inhibitor. It features palmitic acid at the sn-1 position and 13(S)-HODE at the sn-2 position, allowing it to interfere with the binding of 125I-NO2-LDL to CD36-transfected 293 cells, exhibiting an IC50 value greater than 200 μM. This compound is useful for research applications exploring lipid interactions and receptor signaling pathways associated with CD36. -
Anti-CD33 Antibidy
Vadastuximab is a humanized monoclonal antibody that selectively targets CD33, a cell surface protein predominantly expressed on myeloid cells and acute myeloid leukemia (AML) cells. This antibody is instrumental in the development of antibody-drug conjugates (ADCs) designed for targeted therapeutic applications. Research indicates that Vadastuximab can enhance the efficacy of cancer treatments by delivering cytotoxic agents directly to CD33-expressing tumors, thereby promoting precise tumor eradication while minimizing off-target effects. -
CD33 Splicing Modulator
CD33 Splicing Modulator 1 is an innovative agent that targets the CD33/Siglec 3 receptor, a crucial regulator of microglial activity in the myeloid lineage. This compound enhances exon 2 skipping in cellular mRNA, thereby altering CD33 expression. It holds promise as a research tool in neurodegenerative disease studies, particularly in the context of Alzheimer's disease, facilitating a deeper understanding of the underlying mechanisms of these conditions. -
Anti-EpCAM/TROP1/CD326 Antibody
Varsetatug is a humanized IgG1κ monoclonal antibody that targets the epithelial cell adhesion molecule (EpCAM), also known as TROP1 or CD326. This antibody exhibits significant antitumor activity, making it a valuable tool for studying various malignancies, including breast, prostate, and ovarian cancers. Varsetatug is instrumental in cancer research, particularly in investigating therapeutic approaches that exploit EpCAM pathways. -
CD36 Ligand
KDdiA-PC is a highly potent ligand for CD36, primarily targeting the receptor that mediates the cellular response to oxidized low-density lipoprotein (oxLDL). Its significant biological activity facilitates studies on lipid metabolism, inflammation, and atherosclerosis. KDdiA-PC is valuable for researchers investigating the role of CD36 in various physiological and pathological processes. -
CD63-binding Peptide
CP05 is a CD63-binding peptide that specifically interacts with the exosome surface marker CD63. This interaction facilitates the anchoring of exosomes to target tissues, enhancing in vivo delivery of exosomal payloads. CP05 is useful in research applications focused on drug delivery, therapeutic targeting, and the study of exosome biology. -
CD36 Peptide
CD36 Peptide P (139-155), Cys conjugated targets the CD36 protein and serves as a crucial tool for studying its function. This Cys-conjugated peptide is effective in inhibiting the immunoadsorption of CD36 by the OKM5 antibody, making it valuable for research applications focused on immune responses and metabolic processes. The peptide can aid in the investigation of CD36-related pathways and its role in various biological contexts. -
CD36 Peptide
CD36 Peptide P (93-110), Cys conjugated specifically targets CD36, a multifunctional receptor involved in cellular adhesion and lipid metabolism. This peptide has been shown to block the binding of CD36 to immobilized thrombospondin, thereby providing valuable insights into CD36-mediated pathways. Additionally, it partially inhibits collagen-induced platelet aggregation, making it useful for research applications related to cardiovascular function and cell signaling. -
Anti-CD326/EPCAM Antibody
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody that specifically targets the epithelial cell adhesion molecule (EpCAM/CD326), a key player in cell-cell adhesion and signaling. This antibody is suitable for research applications focused on various epithelial cancers, including pancreatic, prostate, and breast cancer. Its ability to interfere with tumor progression and metastasis makes it a valuable tool for studies in cancer biology and therapeutic development. -
Anti-CEACAM5/CEA/CD66e Antibody
Altumomab is a human monoclonal antibody that selectively targets CEACAM5 (carcinoembryonic antigen, CEA) and CD66e. This antibody is primarily utilized in cancer research, particularly for tumor identification and immunotherapy applications. Its specificity for CEACAM5 makes it a valuable tool in the study of various malignancies, enabling enhanced detection and therapeutic strategies against CEA-expressing tumors. -
CD33 Splicing Modulator
CD33 splicing modulator 1 hydrochloride is a small molecule modulator that targets CD33/Siglec 3, a myeloid cell surface receptor that regulates microglial activity. This compound promotes exon 2 skipping in cellular mRNA, making it a valuable tool for investigating the molecular mechanisms underlying neurodegenerative diseases, particularly Alzheimer's disease. It provides researchers with a means to explore potential therapeutic approaches through modulation of splicing events related to CD33. -
Anti-CD19/CD3ε/Albumin Antibody
Faziprumig is a monoclonal antibody that targets CD19, CD3ε, and human serum albumin, exhibiting dissociation constants (Kd) of 0.0738 nM, 7.997 nM, and 0.6 nM, respectively. This reagent effectively activates T cells, leading to their lysis, and demonstrates significant efficacy in targeting and eliminating B-cell malignancies with low CD19 expression. Faziprumig is particularly relevant in the research of non-Hodgkin's lymphoma and various B-cell malignancies. -
CD19/4-1BB Antibody
Englumafusp alfa is a CD19/4-1BB antibody construct designed to enhance immune response by promoting CD19-specific cross-linking of the 4-1BB receptor on T and NK cells. This fusion protein consists of a CD19-specific antibody domain linked to trimerized extracellular domains of human 4-1BB ligand (41BBL). Its key biological activity supports investigations into immuno-oncology applications, particularly in targeting CD19-positive malignancies. Researchers can utilize Englumafusp alfa to study T cell activation and proliferation in the context of cancer therapies. -
Anti-CD19 Monoclonal Antibody
GBR-401 is a humanized anti-CD19 monoclonal antibody that targets CD19 with high affinity for FcγRIIIa. It exhibits potent cytotoxic activity against B-cell malignancies through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and direct cell killing. GBR-401 is effective in depleting malignant B cells and has been shown to prolong survival in various xenograft models using severe combined immunodeficiency (SCID) mice, making it a valuable tool for cancer research and therapeutic development. -
CD2 mAb
BTI-322 is a human IgG1κ monoclonal antibody targeting the CD2 antigen expressed on T cells and natural killer (NK) cells. This reagent demonstrates potent immunosuppressive activity by effectively inhibiting T cell proliferation in response to alloantigens in vitro. BTI-322 is known to recognize a majority of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias, making it suitable for applications in research on renal allograft rejection and steroid-refractory acute graft-versus-host disease. Additionally, BTI-322 serves as a valuable tool for T-cell depletion studies in various immunological contexts. -
Anti-MS4A1/CD20 Monoclonal Antibody
Blidarvetug is a monoclonal antibody that targets MS4A1/CD20, specifically designed for veterinary applications. This reagent is utilized in the investigation of CD20-positive B-cell lymphoma in canine models, facilitating research into the pathophysiology and treatment strategies for this particular type of cancer. Its specificity for CD20 offers valuable insights into B-cell malignancies in veterinary oncology. -
CD20xCD3 Antibody
Imvotamab is a bispecific immunoglobulin M (IgM) antibody targeting CD20 and CD3. It induces T cell activation while preventing excessive stimulation and potential down-regulation of immune responses. This dual-action mechanism makes Imvotamab a valuable tool for research on B-cell malignancies, including multiple myeloma and non-Hodgkin's lymphoma, facilitating studies on immune modulation and therapeutic interventions. -
Anti-CD20 Antibody
BLX-301 is a humanized monoclonal antibody that targets CD20 on B cells. It demonstrates robust anti-tumor activity, making it a valuable tool for research in non-Hodgkin lymphoma and rheumatoid arthritis. This reagent can help elucidate mechanisms of B cell-mediated diseases and contribute to developing targeted therapies. -
Anti-CD79B/CD3E/MS4A1 Antibody
Anafiltamig is a trivalent monoclonal antibody that targets CD79B, CD3E, and MS4A1. This innovative reagent features a humanized IgG1κ anti-CD79B component combined with a bispecific scFv fragment designed to engage CD3E and MS4A1. By simultaneously bridging T and B cells, Anafiltamig activates T cells, leading to the selective elimination of B cell tumors. This compound is particularly useful for research in B cell malignancies, including non-Hodgkin lymphoma. -
CD22 Inhibitor
GSC-718 is a synthetic sialoside and a potent inhibitor of CD22, exhibiting an IC50 value of 0.161 μM for mouse CD22. This compound is known to promote the proliferation of B cells and enhance antibody production. GSC-718 is particularly relevant for research applications involving B-cell lymphoma and autoimmune conditions such as rheumatoid arthritis. -
Anti-CD22 Antibody
RFB4 is an anti-CD22 monoclonal antibody that specifically targets the CD22 antigen, a marker commonly expressed on B-cell malignancies. This antibody can be utilized to generate recombinant immunotoxins by fusing with the pseudomonas exotoxin PE38 through disulfide linkages, such as in the construct RFB4(dsFv)-PE38. RFB4 serves as a vital tool for research focused on cancer, particularly in studies related to lymphoma and other B-cell related diseases. -
CD22 Ligand
CD22 ligand-1 is a potent and selective ligand for CD22, exhibiting a binding affinity (KD) of 0.335 µM for human CD22 and 30.7 µM for myelin-associated glycoprotein (MAG). This compound facilitates the investigation of CD22-mediated signaling pathways and holds potential for advancing research in B-cell related diseases, including autoimmune disorders and lymphomas. Its high specificity for CD22 makes it a valuable tool for understanding the role of this receptor in immunological responses. -
CD276 Monoclonal Antibody
Elfetabart is a humanized monoclonal antibody that specifically targets CD276, exhibiting notable antitumor activity. This antibody belongs to the IgG1κ isotype, making it suitable for various applications in cancer research and therapeutic development. Its interaction with CD276 plays a critical role in modulating immune responses in the tumor microenvironment, thus making it a valuable tool for studying immune evasion and developing immunotherapeutic strategies. -
CD28-B7 Inhibitor
CD28-IN-2 is a selective inhibitor of the CD28-B7 interaction, demonstrating an IC50 of 22.4 μM and a Kd value of 24.1 μM. This compound effectively inhibits CD28-mediated immune activation and prevents T cell costimulation. CD28-IN-2 serves as a valuable tool in research investigating antitumor immunity and various immune-related disorders. -
CD272 Antibody Inhibitor
Radanstobart is a humanized monoclonal antibody that selectively inhibits CD272, a checkpoint protein involved in immune regulation. This antibody exhibits significant antitumor activity, making it valuable for cancer research and immunotherapy studies. It is classified as a human IgG4κ isotype, providing a robust platform for investigating immune responses and potential therapeutic approaches targeting the tumor microenvironment. -
ICOS/CD28 Antagonist
Acazicolcept is an Fc fusion protein that serves as a dual antagonist of the inducible T cell costimulator (ICOS) and CD28. This reagent exhibits significant anti-inflammatory activity, making it valuable for research in autoimmune disorders and T cell modulation. Its unique mechanism of action positions Acazicolcept as a key tool in studying the regulation of immune responses and potential therapeutic interventions.
